TrialNCT04540887ClinicalTrials.gov
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
CompletedNot applicableResults posted 20 Jul 2022
NCT04540887, Not applicable, Completed, Wake Forest University Health Sciences; results first posted 2022-07-20
Cite this record
ConductScience Library. PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome. Trials, record NCT04540887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04540887
- Condition
- Interstitial Cystitis152 trials
- Condition
- Chronic Interstitial Cystitis11 trials
- Condition
- Bladder Pain Syndrome65 trials
- Sponsor
- Wake Forest University Health Sciences1,351 trials
- Sources
- 3 sources
- Release
- trials-2026-11-12-0.5.0
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
- NCT number
- NCT04540887
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10 participants, actual
- Lead sponsor
- Wake Forest University Health Sciences
- Conditions
- Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
- Interventions
- Pulsed Electromagnetic Field (PEMF) Therapy
- First posted
- 2020-09-07
- Last updated
- 2022-12-05
- Results first posted
- 2022-07-20
- Limitations and caveats
The primary limitation of this pilot clinical trial was the small sample size and absence of a control group. We recognize the potential for a significant placebo effect among this patient population. Furthermore, our results are non-generalizable as we evaluated only females, and only those that were considered to have a non-bladder centric IC/BPS phenotype. To mitigate these shortcomings, the next iteration of this trial will employ a randomized, double-blind, sham-controlled study design.
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)
Primary · Baseline before beginning treatment · Mean · score on a scale · Standard Deviation
| Group | Category | Value | Spread | Units |
|---|---|---|---|---|
| Pulsed Electromagnetic Field Therapy (PEMF) | 6.70 | Standard Deviation 0.675 | score on a scale |
Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS)
Primary · Week 12 · Mean · score on a scale · Standard Deviation
| Group | Category | Value | Spread | Units |
|---|---|---|---|---|
| Pulsed Electromagnetic Field Therapy (PEMF) | 4.18 | Standard Deviation 1.462 | score on a scale | |
| Pulsed Electromagnetic Field Therapy (PEMF) | 5.34 | Standard Deviation 1.845 | score on a scale |
Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI)
Secondary · Baseline before beginning treatment, Week 4, and Week 12 · Mean · scores on a scale · Standard Deviation
Baseline
Week 4
Week 12
| Group | Category | Value | Spread | Units |
|---|---|---|---|---|
| Pulsed Electromagnetic Field Therapy (PEMF) | Baseline | 13 | Standard Deviation 1.927 | scores on a scale |
| Pulsed Electromagnetic Field Therapy (PEMF) | Week 4 | 9.125 | Standard Deviation 4.581 | scores on a scale |
| Pulsed Electromagnetic Field Therapy (PEMF) | Week 12 | 10.75 | Standard Deviation 3.742 | scores on a scale |
Change in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA)
Secondary · Baseline, 4-weeks post-treatment, and 8-weeks post-treatment · Median · score on a scale · Inter-Quartile Range
Baseline
4-weeks post-treatment
8-weeks post-treatment
| Group | Category | Value | Spread | Units |
|---|---|---|---|---|
| Treatment | Baseline | 0 | Inter-Quartile Range 0 to 0 | score on a scale |
| Treatment | 4-weeks post-treatment | 2 | Inter-Quartile Range 1 to 2 | score on a scale |
| Treatment | 8-weeks post-treatment | 2 | Inter-Quartile Range 1 to 3 | score on a scale |
Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI)
Secondary · Baseline before beginning treatment, Week 4, and Week 12 · Mean · scores on a scale · Standard Deviation
Baseline before beginning treatment
Week 4
Week 12
| Group | Category | Value | Spread | Units |
|---|---|---|---|---|
| Treatment | Baseline before beginning treatment | 13.875 | Standard Deviation 2.949 | scores on a scale |
| Treatment | Week 4 | 9 | Standard Deviation 4.781 | scores on a scale |
| Treatment | Week 12 | 10 | Standard Deviation 3.741 | scores on a scale |
The charts draw each outcome whole in the first 20 of 24 rows.
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
Participants by period and group
As posted, period by period
Completed the periodDid not complete it
Overall Study
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pulsed Electromagnetic Field Therapy (PEMF) | 10 | |
| Overall Study | COMPLETED | Pulsed Electromagnetic Field Therapy (PEMF) | 8 | |
| Overall Study | NOT COMPLETED | Pulsed Electromagnetic Field Therapy (PEMF) | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
Participants affected
Share of the participants at risk
Total, all-cause mortality
Total, other adverse events
Total, serious adverse events
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pulsed Electromagnetic Field Therapy (PEMF) | 0 | 10 |
| Total, other adverse events | Pulsed Electromagnetic Field Therapy (PEMF) | 0 | 10 |
| Total, serious adverse events | Pulsed Electromagnetic Field Therapy (PEMF) | 0 | 10 |
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Baseline before beginning treatment | The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable"). |
| Primary | Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Week 4 | The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable"). |
| Primary | Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Week 12 | The NRS evaluates average pain intensity. It appears as a horizontal line with an eleven-point range. The NRS is labeled from 0 to 10, with 0 indicating no pain and 10 indicating severe pain ("worst pain imaginable"). |
| Secondary | Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) | Baseline before beginning treatment, Week 4, and Week 12 | The ICPI (score range: 0-16 points) contain four questions related to urinary and pain symptoms. For the problem index, all four questions utilize a range of 0-4 with 0 indicating it is no problem and 4 indicating it is a big problem. Higher scores indicate more severe symptoms and greater disease progression, while lower scores indicate less severe symptoms and less disease progression. |
| Secondary | Change in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA) | Baseline, 4-weeks post-treatment, and 8-weeks post-treatment | The GRA asks participants to list any in-office treatments, home treatments, medications, or procedures they have had in the past year for IC/BPS. Then, they are asked to score those treatments based on a seven point scale (-3 to +3) with -3 indicating their symptoms became markedly worse and +3 indicating their symptoms were markedly improved after treatment. |
| Secondary | Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) | Baseline before beginning treatment, Week 4, and Week 12 | The ICSI (score range: 0-19 points) contains four questions related to urinary and pain symptoms. For the symptoms index, 3 of the 4 questions utilize a range of 0-5 with 0 indicated the symptom is never experienced and 5 indicating the symptom is almost always experienced. The fourth question utilizes a range of 0-4 with 0 indicating the symptom is never experienced and 4 indicating the symptom is almost always experienced. Higher scores indicate more severe symptoms and greater acuity of disease progression, while lower scores indicate less severe symptoms and lower acuity of disease progression. |
| Secondary | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Void and Intake Measurements | Baseline before beginning treatment and Week 4 | Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period. Data analysis will be measured based on urgency score, total urine volume (TUV) (mL), maximum voided volume (MVV) (mL), mean voided volume (mL), and fluid intake (mL). For TUV, MVV, and mean voided volume, higher voided volume (in mL) indicates more efficient bladder-emptying and less severe symptoms, while a lower voided volume (in mL) indicates less efficient bladder-emptying and more severe symptoms. |
| Secondary | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Number of Voids | Baseline before beginning treatment and Week 4 | Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period with sections identifying time of day (with wake time and bed time indicated by participant), fluid intake (type of fluid ingested and amount in oz), urination (amount in oz voided into urinary hat or urinal), amount of urine drained via catheter if applicable, leaks (any time participant experienced involuntary urine loss indicated by a check mark in the corresponding time column) if applicable, and pad changes if applicable. Data analysis will be measured based on daily number of voids (voids). For number of voids specifically, a greater number of voids in a 24-hour period indicates increased urinary frequency and more severe symptoms, while a fewer number of voids in a 24-hour period indicates decreased urinary frequency and less severe symptoms. |
| Secondary | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Urgency Score | Baseline before beginning treatment and Week 4 | Participants will be instructed on how to complete 3-day voiding diary prior to initial office visit and following assessments. The participant will use a new diary sheet for every 24-hour period with sections identifying time of day (with wake time and bed time indicated by participant), fluid intake (type of fluid ingested and amount in oz), urination (amount in oz voided into urinary hat or urinal), amount of urine drained via catheter if applicable, leaks (any time participant experienced involuntary urine loss indicated by a check mark in the corresponding time column) if applicable, and pad changes if applicable. Data analysis will be measured based on urgency score (scale: 0-3, with 0 indicating no urgency and 3 indicating maximum urgency). For the urgency score specifically, lower scores indicate less severe urinary symptoms/urgency while higher scores indicate more severe urinary symptoms/urgency. |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Baseline before beginning treatment | score on a scale | MEAN | |
| PRIMARY | Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Week 4 | score on a scale | MEAN | |
| PRIMARY | Change From Baseline Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) | Week 12 | score on a scale | MEAN | |
| SECONDARY | Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) | Baseline before beginning treatment, Week 4, and Week 12 | Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from the 4- and 8-week post-enrollment data analysis. | scores on a scale | MEAN |
| SECONDARY | Change in IC/BPS Symptoms, as Measured by Wake Forest Baptist Health IC/BPS Global Response Assessment (GRA) | Baseline, 4-weeks post-treatment, and 8-weeks post-treatment | Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from the 4- and 8-week post-enrollment data analysis. Additionally, 1 patient at the 4-week post-treatment evaluation and 3 patients in the 8-week post-treatment evaluation did not specifically list PEMF therapy in the GRA, and therefore their data were excluded from analysis. | score on a scale | MEDIAN |
| SECONDARY | Change in IC/BPS Symptoms, as Measured by O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) | Baseline before beginning treatment, Week 4, and Week 12 | Of 10 participants initially enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. These participants were included in the baseline data analysis but were excluded from Week 4 and Week 12 data analysis. | scores on a scale | MEAN |
| SECONDARY | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Void and Intake Measurements | Baseline before beginning treatment and Week 4 | Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety and one additional participant did not complete her fluid intake. Thus, 6 women had evaluable voiding information and 5 had data for fluid intake to evaluate. | mL | MEAN |
| SECONDARY | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Number of Voids | Baseline before beginning treatment and Week 4 | Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety. | voids | MEAN |
| SECONDARY | Change in IC/BPS Symptoms, as Recorded in Patient Voiding Diary - Urgency Score | Baseline before beginning treatment and Week 4 | Of 10 participants enrolled, 2 experienced exigent personal circumstances and voluntarily withdrew from the study. Their data was excluded from data analysis. Additionally, of the remaining 8 participants, 2 failed to complete their voiding diaries in its entirety. | Score on a scale | MEAN |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Data dates
The day ClinicalTrials.gov processed this copy's newest data, and the day each source was copied for this release.
None in this release
- Adverse events
- Grants
- Trial comparisons
- Tests
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04540887
GET https://conductscience.org/api/trials/v1/NCT04540887/results?page=2